North America Blood Glucose Monitoring System Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America Blood Glucose Monitoring System Market: by Type (Self-Monitoring Blood Glucose Systems, Continuous Glucose Monitoring Systems, Non-Invasive Glucose Monitoring Systems, Biosensor-Based Glucose Monitoring Systems, Smart Glucose Monitoring Devices, Implantable Glucose Monitoring Devices), Application (Hospitals, Home Care, Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Distributors, Others), Technology (Electrochemical, Optical, Enzymatic, Wearable, Non-Invasive, Smart Technology), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20488
North America Blood Glucose Monitoring System Market Outlook 2025–2035
The North America Blood Glucose Monitoring System market is witnessing robust growth driven by technological advancements, rising prevalence of diabetes, and increasing patient awareness regarding the importance of regular glucose monitoring. The market encompasses a wide range of devices including self-monitoring and continuous monitoring systems, smart devices, and non-invasive technologies. With significant investments in healthcare infrastructure, favorable reimbursement policies, and a growing elderly population, market players are focusing on user-friendly and non-invasive solutions. Strategic collaborations among technology firms and healthcare providers are stimulating innovation and increasing accessibility, strengthening the market's growth outlook through 2035.
Latest Market Dynamics
Key Drivers
Rising Prevalence of Diabetes: In North America, the prevalence of diabetes continues to rise. Companies like Abbott Laboratories have reported exponential growth in the adoption of their FreeStyle Libre systems due to the increasing number of diabetic patients in the US and Canada.
Advancements in Non-Invasive Glucose Monitoring: The push towards less invasive, pain-free technologies is accelerating. Dexcom Inc. and Apple are advancing wearable, non-invasive glucose monitoring solutions, making real-time glucose tracking more accessible and comfortable for users.
Key Trends
Integration of AI and Smart Technologies: Companies such as Medtronic Plc are embedding AI and machine learning algorithms into their glucose monitoring systems, enabling predictive analytics for hyperglycemia and hypoglycemia and enhancing patient outcomes.
Growth in Remote Patient Monitoring: The shift towards telemedicine is driving demand for connected glucose monitoring devices. Roche’s collaboration with digital health platforms exemplifies this trend, improving remote care and disease management.
Key Opportunities
Expansion of Direct-to-Consumer Online Channels: With increasing preference for online purchasing and subscription services, players like Dexcom are establishing direct-to-consumer models, improving accessibility and customer engagement.
Adoption in Non-Traditional Settings: Blood glucose monitoring devices are gaining ground in settings including schools, workplaces, and community centers. Abbott's FreeStyle Libre is being adopted in wellness programs, extending the market beyond hospitals and home care.
Key Challenges
Regulatory Hurdles for New Technologies: Companies such as Senseonics face complex FDA approval processes, slowing the market entry of innovative devices and extending commercialization timelines.
Data Privacy and Security Concerns: As smart glucose monitors transmit sensitive health data, firms like Medtronic are investing in cybersecurity solutions to guard against breaches and maintain patient trust.
Key Restraints
High Cost of Advanced Monitoring Devices: Despite proven benefits, the upfront cost of CGM systems from key vendors like Dexcom and Medtronic restricts adoption among price-sensitive consumers and underinsured populations.
Limited Reimbursement in Certain Segments: Coverage gaps impact accessibility, especially for non-invasive monitors. Insurance variability across the US and Canada continues to restrain broader uptake.
Market Share by Type, 2025
Self-Monitoring Blood Glucose Systems (SMBG) maintain dominance in the North America Blood Glucose Monitoring System market, accounting for the largest share. This is attributed to their established usage, cost-effectiveness, and reliability for daily self-management. Continuous Glucose Monitoring Systems (CGM) are rapidly gaining popularity, driven by their real-time monitoring capabilities, improving diabetic outcomes and compliance. Smart and non-invasive technologies are emerging, but are yet to significantly overtake traditional SMBG and CGM devices. As tech adoption increases and pricing moderates, innovative smart and implantable devices are forecasted to rise in market share through 2035.
Market Share by Application, 2025
Hospitals remain the primary application segment for blood glucose monitoring systems, reflecting their central role in acute, perioperative, and critical care management of diabetes. Home care follows closely, illustrating the increasing shift to patient self-management in the region. Clinics and diagnostic centers collectively account for a sizeable portion, supported by point-of-care testing and outpatient diabetes programs. The continued rise of ambulatory surgical centers and other non-traditional environments is expanding the application base, but hospitals and home care are set to dominate in 2025.
Market Revenue (USD Million), 2020–2035
The North America Blood Glucose Monitoring System market revenue reached approximately $5,650 million in 2025, showing consistent growth from $4,300 million in 2020. The market is on track to surpass $9,250 million by 2035, driven by increasing incidence of diabetes, rising healthcare expenditure, and technological innovation. The spike in adoption rates is particularly pronounced after 2023 due to regulatory approvals and improved insurance coverage. Overall, the decade ahead points to robust CAGR supported by ongoing advancements and expanded use in both hospital and home settings.
YOY Growth Rate (%), 2020–2035
Year-over-year growth for the North America Blood Glucose Monitoring System market averages 6.3% between 2020 and 2025, plateauing slightly to approximately 5.1% from 2025 to 2030 as initial adoption surges moderate. Post-2030, CAGR stabilizes around 4.3% as the market matures and replacement demand rises. The initial growth can be attributed to major brand launches and expanding reimbursement, while later years are impacted by price competition and market penetration of smart devices.
Market Share by Country, 2025
The United States dominates the North America Blood Glucose Monitoring System market with a share of 81%, underpinned by high diabetes prevalence, advanced healthcare infrastructure, and greater adoption of innovative technologies. Canada holds 11%, benefiting from robust healthcare coverage and growing device penetration, while Mexico constitutes 8% of the market, supported by government programs and improving access to medical devices. The US remains the primary driver of revenues and technological innovation in the region.
Market Share by Key Players, 2025
Abbott Laboratories leads the North America Blood Glucose Monitoring System market with a 24% share thanks to its FreeStyle Libre series. Dexcom Inc. follows at 20% on the strength of its G7 system and expanding user base. Medtronic Plc holds 16% due to its robust pipeline and hospital partnerships. F. Hoffmann-La Roche and Ascensia Diabetes Care also maintain significant presence, collectively controlling more than a quarter of the market. Strategic investments in R&D, product launches, and partnerships are expected to influence competitive dynamics over the next decade.
Market Share by Buyers, 2025
Hospitals account for the largest buyer share at 41%, reflecting centralized procurement and bulk purchasing. Retail pharmacies hold 27%, illustrating their role in facilitating regular patient purchases of self-monitoring and CGM devices. Online pharmacies are rapidly increasing their share, now at 18%, as consumers embrace online purchases and subscription services. Direct tenders and distributors round out the remaining share, playing key roles in non-hospital settings and broader device distribution.
Abbott Laboratories, F. Hoffmann-La Roche Ltd, Medtronic Plc, Ascensia Diabetes Care Holdings AG, Dexcom Inc., Arkray Inc., B Braun Melsungen AG, ACON Laboratories Inc., Agamatrix Inc., Trividia Health Inc., LifeScan Inc., Sanofi, Nipro Diagnostics Inc., Ypsomed Holding AG
Key Recent Developments
June 2024: Abbott Laboratories announced a partnership with Omada Health to integrate FreeStyle Libre data into digital diabetes management programs across the US.
July 2024: Dexcom Inc. received FDA clearance for its G7 continuous glucose monitoring system expansion for pediatric use.
August 2024: Medtronic plc launched an advanced AI algorithm for real-time hypoglycemia prediction in its Guardian Connect CGM platform.
September 2024: Roche Diagnostics unveiled a strategic alliance with Teladoc Health to bolster remote patient glucose monitoring and telehealth initiatives.
October 2024: Ascensia Diabetes Care Holdings AG introduced a Bluetooth-enabled upgrade for its Contour glucose meters targeting improved connectivity with digital health ecosystems.
